TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Assessment of PET Based Therapeutic Response to HIFU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate on CGI-I
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak small gut motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Analysis of the level of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Physical aptitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal laboratory results
Endpoint domain: Adverse events/effects
Primary endpoint: Positive suicidality outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Two-step Reduction in Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Reporting a Serious Adverse Event (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Flavone metabolites in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Flavone metabolites in urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Major or Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: multi-segmental efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood glucose measurement less than 2.0mmol/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: First stage duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change from baseline in the Clinician Interview-Based Impression of Change plus carer interview [CIBIC-(+)]
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Composite Endpoint feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of death of any cause
Endpoint domain: Mortality/survival
Primary endpoint: Number of Operating Room Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Adherence to European Heart Failure Guideline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Maternal Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Brain activation within the reward circuitry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parental Self-Efficacy for Healthy Dietary and Physical Activity Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opioid regimen adherence
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of repetitions needed to obtain competence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of exams patients receive
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: True Hernia Recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Long-term preservation of ovarian function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lesion remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting Low Density Lipoprotein-cholesterol (LDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Occurrence of Moderate and Severe Chronic GVHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Average numbers of visits required to start ART
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to ART initiation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Electrooculography (EOG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subjective and behavioral data
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of patients who die
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Serum Concentration (Cmax) of Etrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Maximum Serum Concentration (Tmax) of Etrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-Time Curve Within the Last Dosing Interval (AUC-tau) of Etrolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of Congestive Heart Failure (CHF)
Endpoint domain: Mortality/survival
Primary endpoint: Change in evoked force
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Isovlumetric Relaxation Constant - Tau (ms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration in Prone Position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of genetic testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Dose-limiting Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor Response Rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency, duration, and severity of solicited symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of XCEL-MT-OSTEO-ALPHA
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Difference in Intraocular Pressure (IOP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: 7-day Point-prevalence Smoking Abstinence at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-day Point-prevalence Smoking Abstinence at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy Drinking Days at 1 Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heavy Drinking Days at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS analog scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Adequate antibiotic treatment
Endpoint domain: Adverse events/effects
Primary endpoint: intramuscular injection-induced pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction for intramuscular injection
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of Azacitidine
Endpoint domain: Adverse events/effects
Primary endpoint: Lowest Oxygen Saturation (L SO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean Oxygen Saturation (M SO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: SOFA related laboratory order volume
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in complete spontaneous bowel movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin A1C (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Seropositive Subjects for Anti-hepatitis A Virus (HAV) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Anti-diphtheria, Anti-tetanus and Anti-polyribosylribitol Phosphate (PRP) Seroprotected Subjects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Vaccine Responders for Anti-pertussis Toxoid (PT), Anti-filamentous Hemagglutinin (FHA) and Anti-pertactin (PRN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum chromium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum cobalt levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage change in cell cycle-related genetic signature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of post-menstrual spotting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients achieving an SLE Responder Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Obstructive Sleep Apnea Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Urinary hypnotics screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinically Relevant Change in Nasal Examination Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Rated Relief Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Number of Cleared SH Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in size of hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in color of hemangioma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Variation of the ANI index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term outcome measured by SF-36
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of Participants Progression Free at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: mean K-DRS-R98 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inspiratory Muscle Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Postural Control and Balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parkinson's Status- Unified Parkinson's Disease Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confidence in Parenting Skills
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Worst NRS With Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Quantity of Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: High-risk Sexual Behavior: Condomless Sex
Endpoint domain: Adverse events/effects
Primary endpoint: High-risk Sexual Behavior: Sexual Activity During/After Alcohol Use
Endpoint domain: Adverse events/effects
Primary endpoint: Management of type 2 diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in Numeric Pain Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change from baseline in Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dietary quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in minutes of moderate-to-vigorous physical activity (MVPA) per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ovarian response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage of Days Without Symptoms of Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Cumulative Rate of Improvement in Symptoms of Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Severity of Symptoms of Heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Nurse adherence to the depression care management protocol
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Severity of opioid withdrawal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Failed Office Voiding Trials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Vascular Endothelial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Skeletal Toxicities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Condition of feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Face mask acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to premature discontinuation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Disease-Related Symptom Scales of the Quality of Life 30 item core questionnaire (QLQ-C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Kellgren and Lawrence score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Minimal Residual Disease (MRD) eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep Time With Oxygen Saturation Below 90%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Occurrence of acute Graft versus Host disease
Endpoint domain: Adverse events/effects
Primary endpoint: Glycemic Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Weekly Self-reported Alcohol Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant and near visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resolution of Pseudocyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Baseline Tear Breakup Time (TBUT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difficult Access During RIRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of life (Medical Outcomes Short Form-36 (SF-36))
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electroencephalographic (EEG) activities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with bronchospasm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: growth during first three weeks of intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PNQ Grade D or Grade E neurosensory symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Completion rate of CMV monitoring tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With a Favorable Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of preoperative DVTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Incidence of post-operative DVTs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: STAT3 detection in gingival tissues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total and LDL cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in small and medium LDL particles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Correlation between changes in pBCTQ and electrophysiologic severity of CTS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average number of drug abuse instances
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pseudomonas aeruginosa eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Pain and Function (Oswestry Disability Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurologic Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Average length of stay in the hospital
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Who Achieved >75 or Higher PASI Score at 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants Who Achieved IGA Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of patients with major adverse cardiovascular events (MACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Spinal Cord Injury Quality of Life (SCI-QOL) Emotional Domain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Spinal Cord Injury Quality of Life (SCI-QOL) Physical Domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Spinal Cord Injury Quality of Life (SCI-QOL) Social Domain
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: systemic activation of the innate immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: tumor antigen specific T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pathologic complete response
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of contrast-induced nephropathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline in Dopamine Synthesis Capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Uptake of PrEP care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Natural course of HAND
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: surgical intervention time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Plasma fibrinogen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Plasma D-dimer levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Variability in radioiodine kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Classification of fetal status for Trisomy 21
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurophysiological arousal via electroencephalography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: neurophysiological arousal via electrocardiogram
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurophysiological arousal via galvanic skin response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neurophysiological response via respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: neurophysiological response via eye tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 90 day renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Anatomical brain measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Presence of P. aeruginosa in bacterial sputum cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in Stem Cell Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum tolerated dose (MTD) based on number of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with DLTs during the on-treatment period
Endpoint domain: Adverse events/effects
Primary endpoint: Endometrium histology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of any rise in troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of any rise in NT-ProBNP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of any reduction in LV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes